Clinical Trials Logo

Heterotopic Ossification clinical trials

View clinical trials related to Heterotopic Ossification.

Filter by:

NCT ID: NCT01539447 Completed - Clinical trials for Heterotopic Ossification

Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy

Start date: January 2012
Phase: Early Phase 1
Study type: Interventional

In a brief summary the study would like to evaluate the effectiveness of Naproxen in preventing radiographically detected heterotopic ossification following hip arthroscopy for the treatment of femoroacetabular impingement.

NCT ID: NCT00586365 Withdrawn - Clinical trials for Heterotopic Ossification

Naproxen for the Prevention of HO After Complex Elbow Trauma

Naproxen
Start date: October 2007
Phase: Phase 4
Study type: Interventional

Complex elbow fractures can lead to formation of new bone (called Heterotopic ossification). This new bone is unwanted and it can restrict motion. This research study is being done to learn more about the effect of the drug naproxen, on unwanted formation of new bone around the elbow as it heals after a fracture. Naproxen belongs to a class of drugs called NSAIDs which stands for non-steroidal anti-inflammatory drugs. Several research studies suggest that NSAIDs such as Naproxen can prevent the unwanted formation of new bone around the hip. The effect of NSAIDS on the formation of bone around the elbow has not been studied as well as it has been studied for their effect on the hip. The drug, Naproxen is approved by the US food and drug administration (FDA) for sale but ot specifically for the treatment of heterotopic ossification.

NCT ID: NCT00262392 Withdrawn - Clinical trials for Heterotopic Ossification

Study of Pamidronate for the Prevention of Heterotopic Ossification

Start date: June 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether Bisphosphonates in comparison to radiation therapy are effective in the prophylaxis and treatment of heterotopic ossification in high risk patients.